A comprehensive update of ICET-A Network on COVID-19 in thalassemias: what we know and where we stand

Main Article Content

Vincenzo De Sanctis
Duran Canatan
Joan Lluis Vives Corrons
Mehran Karimi
Shahina Daar
Christos Kattamis
Ashraf T Soliman
Yasser Wali
Salam Alkindi
Valeh Huseynov
Afag Nasibova
Tarık Onur Tiryaki
Melike Sezgin Evim
Adalet Meral Gunes
Zeynep Karakas
Soteroula Christou
Mohamed A Yassin
Maria Concetta Galati
Saveria Campisi
Tahereh Zarei
Doaa Khater
Yesim Oymak
Valeriya Kaleva
Denka Stoyanova
Atanas Banchev
Myrto Skafida
Yurdanur Kilinc


COVID-19 pandemic, thalassemias, iron overload, associated co-morbidities, clinical outcome, update.


A review of the literature on COVID-19 pandemic in patients with thalassemias is presented. Globally, the prevalence of COVID-19 among  β-thalassemia patients seems to be lower than in general population; associated co-morbidities aggravated the severity of  COVID- 19, leading to a poorer prognosis, irrespective of age. A multicenter registry will enhance the understanding of COVID-19 in these patients and will lead to more evidence-based management recommendations.


Download data is not yet available.


Metrics Loading ...
Abstract 1608 | PDF Downloads 595


1.Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11. Published 2010 May 21. doi:10.1186/1750-1172-5-11.

2. De Sanctis V, Kattamis C, Canatan D, et al. β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. Mediterr J Hematol Infect Dis. 2017;9(1):e2017018. Published 2017 Feb 20. doi:10.4084/MJHID.2017.018.

3. Cappellini MD, Motta I. New therapeutic targets in transfusion-dependent and -independent thalassemia. Hematology Am Soc Hematol Educ Program. 2017;1:278‐283.

4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease
2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323:1239–1242.

5. Eleftheriou A. Thalassaemia & Sickle Cell Disease: Classification of Risk Groups & Other Considerations
Guidance for Patients, Parents & Healthcare Professionals. 14 May 2020.

6. Canatan D, De Sanctis V. The medical concerns of patients with thalassemias at the time of COVID-19 outbreak: The personal experience and the international recommendations. Acta Biomed. 2020;91:218‐221.

7. Karimi M, De Sanctis V. Implications of SARSr-CoV 2 infection in thalassemias: Do patients fall into the "high clinical risk" category?. Acta Biomed. 2020;91:50‐56.

8. Motta I, De Amicis MM, Pinto VM, et al. SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience [published online ahead of print, 2020 Apr 20]. Am J Hematol. 2020;10.1002/ ajh.25840. doi:10.1002/ajh.25840.

9. Karimi M, Haghpanah S, Azarkeivan A, et al. Prevalence and Mortality due to Outbreak of Novel Coronavirus Disease (COVID-19) in β-Thalassemias: The Nationwide Iranian Experience [published online ahead of print, 2020 Jun 2]. Br J Haematol. 2020;10.1111/bjh.16911.

10. De SanctisV, Canatan D, Vives Corrons JL, et al. Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A Multicentre ICET-A Study. Mediterr J Hematol Infect Dis. 2020 (accepted for publication).

11. Marhaeni W, Wijaya AB, Kusumaningtyas P, Mapianto RS. Thalassemic Child Presenting with Anosmia due to COVID-19 [published online ahead of print, 2020 Jun 9]. Indian J Pediatr. 2020;1. doi:10.1007/ s12098-020-03370-4.

12. Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology. 2020;58:194–196.

13. Mao L, Wang M, Chen S, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. (February 24, 2020). Available at SSRN http://dx.doi.org/10.2139/ssrn.3544840.

14. Goncalves S, Goldstein BJ. Pathophysiology of olfactory disorders and potential treatment strategies. Curr Otorhinolaryngol Rep. 2016;4:115–121.

15. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. Published 2020 Feb 24. doi:10.1038/s41368-020-0074-x.

16.Lee Y, Min P, Lee S, Kim SW. Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients. J Korean Med Sci. 2020;35(18):e174. Published 2020 May 11. doi:10.3346/jkms.2020.35.e174.

17. Thalassemia International Federation .The COVID–19 pandemic and haemoglobin disorders. A contribution of Thalassaemia International Federation to its global patients’ community. https://thalassaemia.org.cy/publications/tif-publications/a-tif-proposed-haemoglobinopathy-patient-pathway-during-the-covid-19-pandemic-2.

18. Vives Corrons JL, De Sanctis V. Rare Anaemias, Sickle-Cell Disease and COVID-19. Acta Biomed. 2020;91(2):216‐217. Published 2020 May 11. doi:10.23750/abm.v91i2.9532.

19.Taher AT, Bou-Fakhredin R, Kreidieh F, et al. Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations [published online ahead of print, 2020 May 11]. Am J Hematol. 2020;10.1002/ajh.25857.

20.Chowdhury SF, Anwar S. Management of Hemoglobin Disorders During the COVID-19 Pandemic. Front. Med.2020;7:306.doi:10.3389/fmed.2020.00306.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 13 > >> 

Similar Articles

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 > >> 

You may also start an advanced similarity search for this article.